文献速递妇科

OVAL研究中期无效性分析:VB-111联合紫杉醇治疗铂耐药卵巢癌

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-02-23

OVAL研究是一项III期双盲随机对照试验,评估靶向抗癌基因治疗VB-111联合周疗紫杉醇治疗铂耐药卵巢癌。预设中期无效性分析显示,VB-111组CA-125缓解率较对照组绝对优势≥10%,独立数据安全监查委员会建议继续试验,未发现新安全性信号。

要点

  • VB-111联合紫杉醇组CA-125缓解率较对照组绝对优势≥10%,达到预设继续标准。
  • 盲态下CA-125缓解率为53%(32/60),完全缓解率15%(9例)。
  • 治疗后发热患者CA-125缓解率达69%,可能为VB-111活性替代标志物。

核心结论

  • 中期分析时缓解率与I/II期研究相似人群中观察到的缓解相当,独立数据安全监查委员会建议按计划继续OVAL试验,未发现新安全性信号。

研究设计与样本

  • OVAL(NCT03398655)为正在进行的III期双盲随机对照试验,患者按1:1随机接受周疗紫杉醇80 mg/m2联合VB-111或安慰剂。
  • 预设对前60例可评估患者按GCIG标准进行CA-125缓解的盲态无效性中期分析,无效性规则为VB-111组缓解率需比安慰剂组至少高10%方可继续研究。

主要发现

  • 可评估患者中位年龄62岁(范围41-82),97%为高级别浆液性癌,58%接受过3线及以上既往治疗,70%既往接受抗血管生成治疗,43%既往接受PARP抑制剂。
  • 盲态结果显示CA-125缓解率为53%(32/60),其中完全缓解15%(n=9)。
  • 假设随机分组均衡且VB-111组绝对优势≥10%,可推断VB-111治疗组缓解率为58%或更高。
  • 治疗后出现发热的患者中,CA-125缓解率为69%。

关键数值与推荐

  • 无效性规则:VB-111组CA-125缓解率需比安慰剂组至少高10%方可继续研究。
  • VB-111联合周疗紫杉醇组CA-125缓解达到预设中期标准,即较对照组绝对优势≥10%。

临床怎么用

  • 中期分析结果支持按计划继续OVAL试验,VB-111联合紫杉醇在铂耐药卵巢癌中显示出活性信号。
  • 治疗后发热可能作为VB-111治疗活性的替代标志物,可供临床监测参考。

局限性

  • 中期分析为盲态设计,VB-111组缓解率58%或更高为基于均衡随机假设的推断值。
  • 样本量仅为前60例可评估患者,结果需最终分析验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Report the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinum resistant ovarian cancer (PROC). METHODS: The OVAL (NCT03398655) study is an on-going study where patients are randomly assigned in a 1:1 ratio to weekly paclitaxel 80 mg/m2 with VB-111 or placebo. The protocol specifies a pre-planned unblinded futility interim analysis of CA-125 response per GCIG criteria in the first 60 evaluable patients. The futility rule determined for this analysis was that the response rate of VB-111 must be greater than the response rate of placebo by at least 10% in order to continue the study. Coincident with the interim analysis, the blinded CA-125 response rate was estimated as a proportion of the first 60 evaluable patients with CA-125 response per GCIG criteria. Post-treatment fever is provided as a possible surrogate marker of VB-111 therapy activity. RESULTS: The median age of the evaluable patients was 62 years (range 41-82); 97% had high-grade serous cancer; 58% had been treated with 3 or more previous lines of therapy, 70% received prior anti-angiogenic treatment, 43% received prior PARP inhibitors. CA-125 response in the VB-111 and weekly paclitaxel treated arm met the pre-specified interim criterion of an absolute advantage of 10% or higher compared to the control. Blinded results show a 53% CA-125 response rate (32/60) with 15% complete response (n=9). Assuming balanced randomization and an absolute advantage of 10% or higher to the VB-111 arm, it may be deducted that the response in the VB-111 treatment arm is 58% or higher. Among patients with post-treatment fever, the CA-125 response rate was 69%. CONCLUSIONS: At the time of the interim analysis, response rate findings are comparable to the responses seen in a similar patient population in the phase I/II study. The independent data and safety monitoring committee (iDSMC) recommended continuing the OVAL trial as planned. No new safety signals were identified.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Arend RC, Monk BJ, Herzog TJ, et al. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecol Oncol. 2021. PMID: 33637348. doi:10.1016/j.ygyno.2021.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。